Join InSphero at SOT 2022
Your most trusted partner for next-generation predictive toxicology and clinical safety
After two years of digital conferences, we are back in person at the Society of Toxicology 61st Annual Meeting and ToxExpo in San Diego!
Meet InSphero Toxicology and 3D cell-based assay experts at booth #1126 to learn how you can leverage tailored 3D in vitro solutions, engineered for:
!New Product Alert: Be the first one to learn about our new all-in-one kit, which we will present at SOT 2022
On year after officially launching the X-Species DILI Validation Consortium, we invite you to the special scientific session, hosted by InSphero on Tuesday, March 29, 12 – 1 PM PT. During the one-hour discussion, Prof. Dr. Armin Wolf, Dr. Bruno Filippi, Dr. Björn Titz, Dr. Simon Plummer, and Dr. Sue Grepper, will discuss the latest advancement within the pre-competitive consortium and the first findings. Mark your SOT agenda and don't miss out on talking to our experts.
Interested in learning about InSphero's vast experience in discovery- and investigative toxicology? Visit our poster sessions at the SOT Exhibit hall, where our Liver Safety team will present the latest findings in liver safety assessment.
Tease out Mechanisms of Toxicity
Talk to our team at SOT to discuss how we can work for you. Our 3D InSight™ Toxicology Platform combines the predictive power of our physiologically relevant liver models with the applications expertise of our scientific staff.
- Standardized DILI Screening
- Custom mechanistic & investigative Studies
- 3D-optimized causality assays for assessing effects of reactive metabolites and oxygen species
- Translational toxicology programs
- Alternatives to animal testing
Conference Detail
March 27-31, 2022
San Diego Convention Center, San Diego, CA, US
Program Information
View the SOT 2022 Program
Download SOT 2022 Event App
Oral Presentations
Exhibitor Hosted Session
The X-Species DILI Validation Consortium: Progress and First Results
Presenters: Prof. dr. Armin Wolf, CSO, InSphero; Dr. Bruno Filippi, VP Liver Safety, InSphero; Dr. Björn Titz, Manager Proteomics and Lipidomics, Philip Morris International; Dr. Simon Plummer, Managing Director, MicroMatrices; Dr. Sue Grepper, Scientific Ambassador, InSphero –Session Moderator
Using animal models to predict human DILI has known issues and high failure rates. The X-Species DILI Validation consortium brings together representatives from biopharma to compare drug effects in regulatory animal models and human 3D in vitro liver models and recapitulate in vivo findings in animals by specific DILI mechanisms to improve the translations. Join the special scientific session to learn about the latest advancement within the pre-competitive consortium and the first findings. Alight assortment of snacks and drinks will be provided, and we look forward to seeing you in the audience!
Poster Presentations
Session: Liver II
10:45 AM – 12:30 PM PT | Exhibit Hall
Poster Number: 4435/P435
Presenting Author: Dr. Sue Grepper, Scientific Ambassador, InSphero
A Rapid 3D In Vitro Screening-Based Discovery Approach for Selecting and Prioritizing NASH Drug Candidates
The aim of the study is to develop a human 3D in vitro NASH spheroid microtissue model, based on a scaffold-free co-culture of primary hepatocytes, Kupffer cells, liver endothelial cells, and hepatic stellate cells for high-throughput-compatible drug efficacy testing.
Session: Safety Assessment: Pharmaceutical-Drug Development II
2:30 PM – 4:15 PM PT | Exhibit Hall
Poster Number: 4809/P874
Presenting Author: Dr. Bruno Filippi, VP Liver Safety, InSphero
3D InSight™ Liver Microtissues as Promising Preclinical Safety Assessment In Vitro Tools: Mechanistic Investigation of Aflatoxin B1 Toxicity in Dog, Rat, and Human 3D InSight™ Liver Microtissues
Awarded as one of Top 10 abstracts at SOT 2022
Animal toxicological studies are an important part of preclinical safety assessment but sometime fail to accurately predict clinical toxicity due to species differences in the uptake, metabolism, or transport of pharmaceutical test compounds. Innovative in vitro tools that recapitulate such species differences would help with the toxicological assessment of novel pharmaceutical test compounds during preclinical safety assessment.
Session: Safety Assessment: Pharmaceutical-Drug Development II
2:30 PM – 4:15 PM PT | Exhibit Hall
Poster Number: 4813/P878
Presenting Author: Dr. Bruno Filippi, VP Liver Safety, InSphero
Mechanistic Investigation of Drug-Induced Liver Toxicity Using Human 3D InSight™ Liver Model
The human 3D InSight™ liver model is more predictive than 2D primary hepatocyte cultures to assess the clinical liver safety of novel pharmaceutical compounds. This new study shows that the human 3D InSight™ liver model can also be used to perform investigation toxicology studies and explore specific mechanisms of toxicity in vitro.
Session: Oxidative Injury and Redox Biology
2:30 PM – 4:15 PM PT | Exhibit Hall
Poster Number: 4308/P242
Presenting Author: Prof. Dr. Armin Wolf, CSO, InSphero
Relation between Oxidative Stress and Antioxidant Defense: Revisited in 3-Dimensional Primary Human Liver Microtissues
In this research we aim to investigate the relationship between menadione-induced toxicity and the antioxidant status of the liver (defined as GSH-content) by implementing 3D primary human liver microtissues (hLiMTs)